A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
Clinical trial NCT07431216 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07431216
- Sponsor
- Starlight Therapeutics Inc.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-01
- Primary completion
- 2027-05-01
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.